Abstract Leishmaniasis is a parasitic disease caused by several species of the genus Leishmania. Montanide ISA 70 is an adjuvant composed of a natural metabolizable oil and a very refined emulsifier from the manide monooleate family. The TSA (thiol-specific antioxidant) is a important antigen of Leishmania major. The purpose of this work was proteinvaccine efficacy as an protection and excellent candidate in the presence Montanide. The expression of recombinant protein was confirmed with SDS (sodium dodecyl sulfate) page and Western bloting. 48 BALB/c mice were divided into four groups (TSA/Freund,TSA/Alum ? BCG, TSA/ Montanide and PBS groups) and immunized with 20 lg of vaccine subcutaneously three times intervals on days 0, 14 and 28. The mice were challenged with parasite 21 days after final immunization. The lymphocyte proliferation was evaluated with Brdu method. Cytokines and also total antibody and subclasses were evaluated with ELISA method. The vaccine formulated with the recombinant TSA protein with Montanide induced lymphocytes proliferation cytokines and total antibody and subclasses as compared with the control group.
Introduction
Leishmaniasis is caused by parasitic protozoa of the genus Leishmania which, in the infected host are obliging intracellular parasite. In this group Leishmania major is the etiological agent of cutaneous leishmaniasis that is prevalent in many tropical and subtropical areas of the world. The disease has a high incidence rate in Iran (Alvar et al. 2012; Farahmand et al. 2011) . The manifestation of disease is varying from self-limiting with life-long immunity to developing shape as chronic disease. When Leishmaniasis accompanied by deficient cellular immunity, the disease can improve to chronic shape (Von Stebut 2007; Douba et al. 2012) .The number of new cases of cutaneous leishmaniasis is estimated a range from 0.7 to 1.2 million.The HIV (human immunodeficiency virus) and Leishmania co infection is reason of rapidly growing of Leishmaniasis in regions where Leishmania species are endemic. In the other hand toxicity of chemotherapy and currently available drugs for treatment haven't shown ideal consequence and ever important, resistance to current drugs, above all things underline to need for a safe, effective vaccine (Coler and Reed 2005; Masina et al. 2003) . In recent years with completion of genome sequencing of L. major, researchers find out that some of genes are expressed in the infectious stages of the parasite and in particular, in amastigotes, which can help to design effective vaccines (khamesipour et al. 2006 ). Among L. major antigens as vaccine candidate, TSA (thiolspecific-antioxidant) with molecular weight of 22.1 kDa has been introduced as one of the predominant and one of the important immune system stimulator, homologue to eukaryotic TSA protein. Recombinant form of TSA protein composed of 200 amino acids and placed in the chromosome of 15 of L. major and is full gene with multiple copy in chromosome. Distribution of TSA protein on the surface of both extracellular and intracellular promastigote and amastigotes is important and in BALB/c mice model infected with L. major can persuade Th1 response comparing to the other selected antigens. TSA protein induces strong cellular immune response resulted in protective immunity (mauel 2002; Campos-Neto et al. 2001 ,2002 Webb et al. 1998) . Montanide (Incomplete Seppic adjuvants), is an oil adjuvant composed of a natural metabolizable oil and a highly refined emulsifier from the manide monooleate family. Montanide incomplete seppic adjuvants, are a group of oil/ surfactant based adjuvants in which different surfactants are combined with either a non-metabolizable mineral oil, a metabolizable oil, or a mixture of the two oils. Vaccine formulations with Montanide induce a strong and long term immunity. Compared to traditional oil emulsions, Montanide emulsions are stable and easy to inject which are having high immunopotentiation capacity and showing lesser side-effects are valid (Aucouturier et al. 2001 (Aucouturier et al. , 2002 Toledo et al. 2001; Joshua et al. 2010) . In this report we described novel protein vaccine immune responses elicited.
Material and method
Expression and purification of the recombinant TSA protein TSA sequence was optimized and then the sequence was purchased from Biomatik Company (Canada). TSA gene was double digested and after purification of gene, it was subcloned into the pET28a expression vector using ligase enzyme. In order to express the recombinant protein, pET28a-TSA expression vector was transformed into the E. coli BL21 (DE3) using electroporation technique. Culture of E. coli BL21 (DE3) containing pET28a-TSA recombinant plasmid was done in the present of IPTG 1 mM for 4 h. The expression of recombinant protein was confirmed with SDS-PAGE and also via Western blot technique. Recombinant protein was purified with nickel affinity chromatography (Tabatabaie et al. 2007; Bradford, 1976) .
Preparation adjuvant
Montanide 70 VG (Seppic france) was used at an adjuvant mixtured with antigen at ratio of 30/70 (v/v) TSA/Montanide, TSA/BCG-Alum, TSA/Freund and control PBS groups. Twelve mice in each group were anesthetized with 25 lL g -1 of mixture of ketamin 10 % and xylazin 2 % via intraperitoneal (i.p.) injection and were immunized with 100 lL of administration content according to their grouping(20 lg of recombinant protein TSA vaccine and 40 lg of adjuvants) subcutaneously three times intervals on days 0, 14 and 28. Finally,immune responses 3 weeks after the last injection were valuated. The mice were challenged at the base of tail by the intradermal route with 2 Á10 6 promastigotes of L. major 21 days after final immunization. The Immune responses 3 weeks after challenge were valuated (Rosado-Vallado et al. 2005 ).
Cell preparation
Responses of specific and proliferation lymphocytes to Brdu technique was done. Spleen was removed from euthanized mice 3 weeks after the last immunization and 3 weeks after the challenge infection. The tissues were macerated and washed in RPMI 1640 and incubated for five minutes in 0.17 M Tris pH 7.2 and 0.16 M NH4Cl to lyses erythrocytes. The splenocytes were washed and resuspended in RPMI 1640 supplemented with 20 mM sodium pyruvate, 5 9 10 5 M mercaptoethanol, 4 mM glutamine, 10 % bovine fetal serum, 100 U/ml penicillin and 100 lg/ml streptomycin. The cell's viability and number were assessed in an improved Newbauer chamber using 0.4 % Trypan blue.
Cytokines assay before and after the challenge infection with L. major
The splenocyte cultures and cytokine assays were performed. Briefly, single-cell preparations from the spleen tissue were plated in duplicate in 24-well plates (Nunc) at 2 9 10 6 cells/ml. The cells were incubated in DMEM (Dulbecco modified eagle medium ) alone (background control). Then the cells were stimulated in triplicate with soluble L. major antigen separately stimulated with SLA (soluble Leishmania antigen) from L. major (20 lg/ml), at 37°C in 5 % CO 2 for 48 h. The SLA-stimulated cells presented stimulation indexes in the range of 3.5-3.7 for the spleen cells. SI (Stimulated index) greater than 2.5 indicated a positive response. Levels of IFN-c and IL-4 in the supernatants were assessed by sandwich ELISA (enzyme-linked immunosorbent assay) using Inter Test mouse IFN-c and IL-4. [ELISPOT Kit]. All the tests were performed in triplicate for mice ).
Detection of antibody responses before and after the challenge infection with L. major
The blood samples were collected by retro-orbital puncture from the immunized mice 3 weeks after immunization and 3 weeks after challenge infection. The samples were centrifuged in 3,000 rpm for 15 min for serum preparation. The sera were tested for the presence of total anti-L. major IgG antibodies by ELISA. Briefly, the microtitre plates were coated overnight at 4°C with soluble L. major antigens (10 lg/ml) in 100 mM carbonate-bicarbonate buffer pH 9.6 (100 lL per well) and sealed. The plates were washed in PBS (pH 7.4). Blocking was carried out with 1 % dried skim med milk in PBS (pH 7.2) for 1 h at 37°C. After washing with PBS containing 0.05 % Tween 20 (PBST20), the sera were diluted 1/200 in 1 % dried skimmed milk-PBST20 (100 lL per well) and incubated for 1 h and 30 min at 37°C. After washing, the bound antibodies were detected by incubation at 37°C for 1 h and 30 min with HRP (horseradish peroxidase)-labeled goat anti-mouse IgG (DAKO,Denmark) at 1/2,000 dilution in 1 % dried skimmed milkPBST20 (100 lLper well). Peroxidase activity was revealed by adding 100 lL per well of (TMB) tetra methyl benzidine substrate. The reaction was stopped after 15 min with adding 100 lL of 2 MH2SO4 and the (OD) optical density was read at 450 nm in an ELISA micro plate reader (Bio-Rad,USA). Specific IgG1 and IgG2a subclasses were detected using goat anti mouse IgG1 and IgG2a secondary antibodies (Sigma, USA) according to the manufacture's instruction (Sasaki et al. 2003 , Buffer 1995 .
Statistical analysis
Statistical comparisons between the experimental groups were carried out with an analysis of variance (ANOVA) and post hoc Turkey test. Differences were statistically considered significant when p values was less than 0.05 (p \ 0.05).
Results
Our results showed that recombinant protein was produced in the E. coli BL21 (DE3) containing pET 28a-TSA plasmid after induction with 1 mM IPTG that expression of recombinant protein was confirmed with SDS page and Western blot analysis (a * 22 kDa band). In the next, we intended that use this protein as a vaccine candidate against Leishmania infection in BALB/c mouse model.
To evaluate the proliferative responses of lymphocytes was used to Brdu test. The 3 weeks after three protein vaccination the proliferative responses of lymphocytes markedly were increased in the vaccinated groups, which were significantly higher than in control group. (P \ 0.05). Before and after challenge infection in the vaccinated groups were no statistical significant difference but was statistical significant difference with control group (Fig. 1) .
We analyzed the levels of IFN-c and IL-4 production in the supernatants of the spleen cells of all the 4 groups 3 weeks after immunization and 3 weeks after challenge infection with L. major. The 3 weeks after three protein vaccination IFN-c values markedly increased in the vaccinated groups, which were significantly higher than in the control group (p \ 0.05). Between vaccinated groups were no statistical significant difference (p [ 0.05). After challenge infection IFN-c values markedly increased in the vaccinated groups, which were significantly higher than in the control group (p \ 0.05). Between the vaccinated groups were no statistical significant difference (p [ 0.05) (Fig. 2) . Before booster injection and after challenge with L. major IL-4 values significant differences were not observed between vaccinated and control groups (p [ 0.05). Though before booster injection and after challenge IL-4 values increased in the vaccinated groups but there were no statistically significant differences between vaccinated and control groups (p [ 0.05) (Fig. 3) .The sera were collected from the immunized and control mice 3 weeks after the final booster injection and 3 weeks after the challenge infection, tested for the presence of total IgG antibodies by indirect ELISA method. Figures 4, 5 showed that the humeral responses were elicited by the immunization before and after the challenge infection. Before booster and after challenge anti-L. major IgG values markedly increased in TSA/Montanide group, which was significantly higher than in control group (p \ 0.05) but significant differences were not observed between vaccinated groups. Figures 6, 7 Results of IgG isotyping before and after challenge showed that all vaccine immunized groups significantly increased IgG1, IgG2a subclasses as compared to the control group (P \ 0.030).
Discussion
Leishmaniasis is prevalent in many parts of the world, with about 12 million total cases worldwide. As many as 1.5-2 million new cases of cutaneous leishmaniasis and 5,00,000 cases of visceral leishmaniasis are reported every year (Handman 2001) . In view of the emerging drug resistance, the development of safe and efficient vaccines remains to be the best hope for achieving definitive control of leishmaniasis. Immunity against re infection is acquired following cutaneous infection with Leishmania spp., suggesting that prophylactic immunization is feasible. A number of vaccine strategies have been tested, ranging from killed parasites to recombinant antigens or DNA or protein vaccines. No protective and effective anti-Leishmania vaccine is available at the moment in spite of several tested vaccine protocols despite enormous effort of researchers to preparation of effective vaccine formula there is no protective vaccine and this failure turned to cell mediated immune system response in primarily impact to parasite (Handman 2001; Campos-Neto et al. 2001) . In this level vaccine progresses strategy against L. major depends on proper and good defined antigen (s) and application of strong adjuvant in vaccine formulation to reach optimal immunity results.The availability of hundreds of adjuvants has prompted a need for identifying rational standards for the selection of adjuvant formulation based on immunological principles for human vaccines (Benhnini et al. 2009 ). TSA family from humans to Saccharomyces cerevisiae has conserved domains and distinctive similarity in amino acid sequence has been seen in this group. S. cerevisiae TSA confer safety against oxidative stress and damage. Mechanism of TSA action embedded in a thiol oxidation-based enzyme inhibition mode. Function of TSA protein depend on thioredoxin, thioredoxin reductase, and NADPH as reducing equivalents, then been define as thioredoxin peroxidase. Thioredoxin as a reducing equivalent In S. cerevisiae help to reduction of H2O2 molecules and participate in protection of mechanism against peroxidemediated oxidative damage Similar situation occurs inside macrophages. Respiratory burst in macrophages mediated by production of H2O2 and TSA molecules as leishmania product, guarantee Leishmania survival inside the macrophages. (Mendez et al. 2002; Chae et al. 1993 , Chae et al. 1994a Netto et al. 1996; James and Nacy 1993; Mehlotra, 1996; Ahmed et al. 2004 ). The recombinant leishmanial antigens LmSTI1 and TSA have been shown that they can induce excellent protection in both murine and non human primate models of human cutaneous leishmaniasis. The recombinant TSA protein with IL-12 induces excellent protection in the BALB/c mice recombinant proteins, LACK and TSA have produced at least partial protection against L. major in BALB/c mice Mougneau et al. 1995) . Successful immunization that induces protection against leishmaniasis is highly dependent on adjuvant that preferentially stimulates (Qiu et al. 2008) . In this study our results showed that proliferative responses of lymphocytes and IFN-c values before and after challenge infection in the vaccinated groups were no statistical significant difference but was statistical significant difference with control group but in IL-4 values significant differences were not observed between vaccinated and control groups. Before booster and after challenge anti-L. major IgG values markedly increased in TSA/Montanide group, which was significantly higher than in control group but significant differences werenot observed between vaccinated groups. While Campos-Neto et al. 2001 , 2002 , 2005 .
In this study, we demonstrated that Montanide can effect on efficacy of a protein vaccine-encoding TSA against L. major infection and elicits humeral and cellular immune responses. The vaccine formulation described here may be an protection and excellent candidate for further vaccine development.
